Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades

Group 1 - Gilead Sciences Inc. is recognized as one of Goldman Sachs' top healthcare stocks, with Jefferies initiating coverage with a Buy rating and a $180 price target, highlighting the company's earnings-per-share growth and margin-expansion prospects [1] - The company is well positioned with its HIV franchise and has promising prospects for follow-on products, particularly with the launch of Yetzugo in pre-exposure prophylaxis [1] - Gilead Sciences is making significant progress in its pipeline development, with the phase 3 RAINIER trial for drug povetacicept meeting primary and secondary endpoints for treating immunoglobulin A nephropathy (IgAN) [2] Group 2 - Gilead has entered into a $7.8 billion deal to acquire blood cancer drug developer Arcellx, following a partnership established in 2022 for the commercialization of medicines targeting multiple myeloma [2] - The company is a US-based biopharmaceutical firm focused on discovering, developing, and commercializing innovative medicines for life-threatening diseases, particularly in virology, oncology, and inflammation [3] - Gilead is known for its leadership in antiviral therapies for HIV, Hepatitis B and C, and COVID-19, with a strong emphasis on expanding its global impact, including in Asia [3]